Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
syh2062
- Development stage
- Phase 1
- Lead developer
- CSPC Zhongnuo Pharmaceutical
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SYH2062 is a double-stranded small interfering RNA (siRNA) therapeutic developed by CSPC ZhongNuo Pharmaceutical for the treatment of hypertension. The drug is delivered via N-acetylgalactosamine (GalNAc) conjugation, which enables targeted delivery to hepatocytes. Its mechanism of action involves targeting and inhibiting angiotensinogen (AGT), leading to reduced production of angiotensin II, a key regulator in blood pressure control. Preclinical studies have shown that SYH2062 can achieve over 90% reduction in serum AGT protein levels and lower systolic blood pressure by approximately 20% for more than four months in hypertensive monkeys. The drug is designed for long-lasting efficacy with the potential for administration once every six months, aiming to improve medication adherence and provide sustained antihypertensive effects[1][5][6].
- Other names
- SYH 2062SYH2062SYH-2062
02
Targets
AGT (O6-methylguanine-DNA methyltransferase)
Beyond the preview
Go deeper on syh2062.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on syh2062.